JP2017512753A - 炎症性貧血の処置におけるパリカルシトールの使用 - Google Patents

炎症性貧血の処置におけるパリカルシトールの使用 Download PDF

Info

Publication number
JP2017512753A
JP2017512753A JP2016552329A JP2016552329A JP2017512753A JP 2017512753 A JP2017512753 A JP 2017512753A JP 2016552329 A JP2016552329 A JP 2016552329A JP 2016552329 A JP2016552329 A JP 2016552329A JP 2017512753 A JP2017512753 A JP 2017512753A
Authority
JP
Japan
Prior art keywords
paricalcitol
esa
patients
levels
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016552329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512753A5 (enExample
Inventor
リベラ，ミゲール ジョバンニ ウリオール
リベラ，ミゲール ジョバンニ ウリオール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2017512753A publication Critical patent/JP2017512753A/ja
Publication of JP2017512753A5 publication Critical patent/JP2017512753A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2016552329A 2014-02-11 2015-01-16 炎症性貧血の処置におけるパリカルシトールの使用 Pending JP2017512753A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP201430177 2014-02-11
ES201430177A ES2472040B1 (es) 2014-02-11 2014-02-11 Uso de paricalcitol en el tratamiento de la anemia inflamatoria
PCT/EP2015/050817 WO2015121022A1 (en) 2014-02-11 2015-01-16 Use of paricalcitol in the treatment of inflammatory anaemia

Publications (2)

Publication Number Publication Date
JP2017512753A true JP2017512753A (ja) 2017-05-25
JP2017512753A5 JP2017512753A5 (enExample) 2018-02-22

Family

ID=51205045

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016552329A Pending JP2017512753A (ja) 2014-02-11 2015-01-16 炎症性貧血の処置におけるパリカルシトールの使用

Country Status (16)

Country Link
US (1) US11464791B2 (enExample)
EP (1) EP3104872B1 (enExample)
JP (1) JP2017512753A (enExample)
KR (1) KR20160113664A (enExample)
CN (1) CN106061498B (enExample)
AR (1) AR099330A1 (enExample)
AU (1) AU2015217956B2 (enExample)
CA (1) CA2938057A1 (enExample)
DK (1) DK3104872T3 (enExample)
ES (2) ES2472040B1 (enExample)
IL (1) IL247207B (enExample)
MX (1) MX365096B (enExample)
PT (1) PT3104872T (enExample)
RU (1) RU2016131412A (enExample)
UY (1) UY35989A (enExample)
WO (1) WO2015121022A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102504090B1 (ko) * 2020-08-05 2023-02-24 경상국립대학교병원 조영제-유발 신독성 예방 또는 치료용 약학 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008508854A (ja) * 2004-04-23 2008-03-27 ケンブリッジ アンティボディー テクノロジー リミテッド エリスロポイエチンタンパク質変異体
JP2010515736A (ja) * 2007-01-10 2010-05-13 エジソン ファーマシューティカルズ， インコーポレイテッド エリスロポイエチン活性またはトロンボポイエチン活性を有する化合物を用いる呼吸鎖障害の治療

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062620A2 (en) * 2003-01-13 2004-07-29 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
CN102772364B (zh) * 2011-05-13 2015-12-02 重庆华邦制药有限公司 帕立骨化醇的脂肪乳及其制剂和制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008508854A (ja) * 2004-04-23 2008-03-27 ケンブリッジ アンティボディー テクノロジー リミテッド エリスロポイエチンタンパク質変異体
JP2010515736A (ja) * 2007-01-10 2010-05-13 エジソン ファーマシューティカルズ， インコーポレイテッド エリスロポイエチン活性またはトロンボポイエチン活性を有する化合物を用いる呼吸鎖障害の治療

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ＡＳＡＩＯ ＪＯＵＲＮＡＬ, vol. Ｖｏｌ. ４９ Ｉｓｓｕｅ ２, JPN6018035464, 2003, pages 194, ISSN: 0004026578 *
ICARDI A: "RENAL ANAEMIA AND EPO HYPORESPONSIVENESS ASSOCIATED WITH VITAMIN D DEFICIENCY: 以下備考", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. VOL:28, NR:7,, JPN5017000710, 6 March 2013 (2013-03-06), pages 1672 - 1679, ISSN: 0004026579 *

Also Published As

Publication number Publication date
ES2472040R1 (es) 2014-09-18
IL247207B (en) 2020-02-27
US11464791B2 (en) 2022-10-11
AU2015217956B2 (en) 2019-04-04
ES2728158T3 (es) 2019-10-22
US20160367571A1 (en) 2016-12-22
ES2472040B1 (es) 2015-07-01
RU2016131412A (ru) 2018-03-15
CN106061498A (zh) 2016-10-26
MX365096B (es) 2019-05-22
CA2938057A1 (en) 2015-08-20
DK3104872T3 (da) 2019-06-17
UY35989A (es) 2015-03-27
ES2472040A2 (es) 2014-06-27
KR20160113664A (ko) 2016-09-30
CN106061498B (zh) 2019-12-06
AR099330A1 (es) 2016-07-13
IL247207A0 (en) 2016-09-29
PT3104872T (pt) 2019-06-11
MX2016010104A (es) 2017-01-06
WO2015121022A1 (en) 2015-08-20
EP3104872A1 (en) 2016-12-21
AU2015217956A1 (en) 2016-08-25
EP3104872B1 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
Drüeke et al. Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients
Coyne et al. Differential effects of acute administration of 19-Nor-1, 25-dihydroxy-vitamin D2 and 1, 25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients
Gottschlich et al. Clinical trial of vitamin D2 vs D3 supplementation in critically ill pediatric burn patients
Iguchi et al. Administration of ferric citrate hydrate decreases circulating FGF23 levels independently of serum phosphate levels in hemodialysis patients with iron deficiency
US20040043971A1 (en) Method of treating and preventing hyperparathyroidism with active vitamin D analogs
Hecker et al. Management of osteoporosis in adults with cystic fibrosis
JP2016179994A (ja) イネカルシトールの新しい治療的使用
Luo et al. Impact of tacrolimus on bone metabolism after kidney transplantation
Akizawa et al. Long-term effect of 1, 25-dihydroxy-22-oxavitamin D3 on secondary hyperparathyroidism in haemodialysis patients. One-year administration study
Mori et al. The effect of active vitamin D administration on muscle mass in hemodialysis patients
RU2576511C2 (ru) Пероральная терапия недостаточности витамина в12
AU2025259887A1 (en) Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein
AU2015217956B2 (en) Use of paricalcitol in the treatment of inflammatory anaemia
Pandey et al. Use of 2MD, a novel oral calcitriol analog, in hemodialysis patients with secondary hyperparathyroidism
Tidblad et al. Metabolic effects of growth hormone treatment in short prepubertal children: a double-blinded randomized clinical trial
Shomali et al. Hypercalcemia in a woman with hypoparathyroidism associated with increased parathyroid hormone-related protein during lactation
JP6279529B2 (ja) 虚弱を治療する方法
Mitsopoulos et al. Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism
Nair et al. Vitamin D status and supplementation in adult patients receiving extracorporeal membrane oxygenation
Bashardoust et al. Treatment effect of ergocalciferol on bone metabolism indexes and parathyroid hormone in hemodialysis patients
Abu-Hamdan et al. Zinc tolerance test in uremia: effect of calcitriol supplementation.
Ziólkowska Minimizing bone abnormalities in children with renal failure
Rubin et al. TransCon PTH as a Hormone Replacement Therapy for Patients with Hypoparathyroidism: 6-Month Update from the PaTH Forward Open-Label Extension
LLACH TREATMENT OF SECONDARY HYPERPARATHYROIDISM BY INTRAVENOUS
JPH08507073A (ja) カルシウム代謝障害の治療のための２６，２６，２６，２７，２７，２７−ヘキサフルオロ−１アルファ，２５−ジヒドロキシコレカルシフェロールの使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160906

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20160927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180912

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190507